<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364325">
  <stage>Registered</stage>
  <submitdate>27/05/2013</submitdate>
  <approvaldate>29/05/2013</approvaldate>
  <actrnumber>ACTRN12613000613707</actrnumber>
  <trial_identification>
    <studytitle>Effect of Testosterone Therapy Combined with Very Low Caloric Diet on Weight Loss and Weight Maintenance in Obese Men: A Randomized Controlled Trial</studytitle>
    <scientifictitle>Effect of Testosterone Therapy Combined with Very Low Caloric Diet on Weight Loss and Weight Maintenance in Obese Men: A Randomized Controlled Trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity

</healthcondition>
    <healthcondition>Low testosterone</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>56 weeks Randomised, Placebo-controlled Trial of Testosterone Replacement Therapy in combination with a very low calorie diet

Intramuscular testosterone undecanote, 1000mg delivered IM at baseline, week 6, 16, 26, 36 and 46 by study investigators

Optifast very low calorie diet administered for the first 8 weeks concurrently with the injections, providing approx 600-700 calories per day.  A serve of non-starchy vegetables is encouraged to assist with hunger.  Study participants are reviewed every 2 weeks by the doctor when on the very low calorie diet to review compliance and any adverse effects from the diet.  These visit take approx 30 minutes.  After the very low calorie diet phase, subjects are seen every 10 weeks, these visits take 30 minutes.  In addition, visits at baseline, week 10 and week 56 take 3 hours.  


</interventions>
    <comparator>Placebo is 4 mls of oily base, indistinguishable from testosterone undecanoate

All participants recieve the very low calorie diet</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Weight loss using calibrated digital scales</outcome>
      <timepoint>56 weeks after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Weight maintenance using calibrated digital scales</outcome>
      <timepoint>56 weeks after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition by DEXA</outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Visceral fat by single- slice CT scan at L4-5 </outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Muscle strength by handgrip dynamometer</outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gut hormones by serum assay</outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exercise level by accelerometer</outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hypogonadal symptoms by validated questionnaire  (Aging males symptoms)</outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gene changes in fat by microarray / PCR</outcome>
      <timepoint>2 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male sex, age 18-75 years, BMI 30-60 kg/m2and testosterone &lt;12nmol/L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>established pituitary or testicular disorders, contraindications to testosterone therapy including androgen-dependent carcinoma of the prostate or of the male mammary gland, known malignancy, hypersensitivity to the active substance or to any of the excipients, polycythemia (haematocrit&gt;55%), known liver tumour, significant benign prostate hypertrophy, prostate specific antigen (PSA) &gt; 4ng/ml, uncontrolled hypertension (&gt;160/90 mm Hg despite anti-hypertensive medication, uncontrolled untreated sleep apnoea, severe disturbance in renal function (estimated glomerular filtration rate &lt;30 ml/min), uncontrolled epilepsy, migraine, or significant cardiac insufficiency (New York Heart Association performance status &gt;2), coagulation disorders, current use of weight-altering medications (thiazolidinediones, systemic glucocorticoids, antipsychotics, topiramate), unstable thyroid dysfunction (stable = normal TFT on thyroxine dose &gt;3/12), Cushings disease; past history of bariatric surgery</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Enrollment via the study co-ordinators at the Repatriation hospital, Heidelberg, Victoria

Randomisation by Pharmacy Department.  Vials will be coded and identifiable by number.  Austin Helath Pharmacy, but not the researchers or study subjects involved in the trial will be aware of the code. </concealment>
    <sequence>The study will be conducted as a double-blind, randomised design.  A standard block randomisation procedure will be used to ensure that the final design is very close to, if not exactly, balanced.  Men will be stratified according to BMI &lt;=37 or &gt;37 and age &lt;=60y or &gt;60y</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>15/04/2013</anticipatedstartdate>
    <actualstartdate>15/02/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>8/09/2014</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>9/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Austin Health - Heidelberg Repatriation Hospital - Heidelberg West</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Melbourne</primarysponsorname>
    <primarysponsoraddress>Department of Medicine, University of Melbourne, Austin Health, 145 Studley Rd, Heidelberg, VIC 3084
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Melbourne</fundingname>
      <fundingaddress>Department of Medicine, University of Melbourne, Austin Health, 145 Studley Rd, Heidelberg, VIC 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer Pharmaceuticals</fundingname>
      <fundingaddress>Bayer Healthcare Pharmaceuticals
875 Pacific Highway, Pymble, NSW, 2073
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Obesity, an increasing health and economic burden in Australia, is associated with lowered
circulating testosterone (T) levels in men.  While both dietary restriction and T treatment reduce body fat, whether a combination of these two approaches achieves a more pronounced fat mass reduction is unknown.  We will conduct a randomised placebo-controlled trial (RCT) of 12 months T treatment in 100 obese men (defined as body mass index (BMI) &gt; 30kg/m2) with a low T level (defined as serum total T &lt; 12 nmol/L).  All men will receive structured dietary intervention to induce and maintain weight loss.
</summary>
    <trialwebsite />
    <publication>Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial

Ng Tang Fui, Mark
Prendergast, Luke A.
Dupuis, Philippe
Raval, Manjri
Strauss, Boyd J.
Zajac, Jeffrey D.
Grossmann, Mathis

DOI 10.1186/s12916-016-0700-9

ISSN 1741-7015

BMC medicine 14:1 153-164</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health, Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 6 HSB, Austin Health 
Studley Rd, Heidelberg 3084 Vic 
</ethicaddress>
      <ethicapprovaldate>21/03/2013</ethicapprovaldate>
      <hrec>H2012 / 04495, H2008 / 03330</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Mathis Grossmann</name>
      <address>Department of Medicine, Austin Health, 145 Studley Road, Heidelberg, VIC 3084</address>
      <phone>+61394965000</phone>
      <fax />
      <email>mathisg@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mark Ng Tang Fui</name>
      <address>Department of Endocrinology, Austin Health, 145 Studley Road, Heidelberg VIC 3084</address>
      <phone>+61394962082</phone>
      <fax />
      <email>mark.ng@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mark Ng Tang Fui</name>
      <address>Department of Endocrinology, Austin Health, 145 Studley Road, Heidelberg VIC 3084</address>
      <phone>+61394962082</phone>
      <fax />
      <email>mark.ng@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mark Ng Tang Fui</name>
      <address>Department of Endocrinology, Austin Health, 145 Studley Road, Heidelberg VIC 3084</address>
      <phone>+61394962082</phone>
      <fax />
      <email>mark.ng@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>